ReviewAdvances in therapy2016
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Review in Advances in therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 57 citations in OpenAlex.
- Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.Advances in therapy · 2017Trial
- Effect of emulsion-based nanosystems on the encapsulation behavior of triptorelin using molecular dynamics simulation.Journal of computer-aided molecular design · 2026Article
- Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics.PloS one · 2026Article
- Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases.Frontiers in pharmacology · 2026Article
- Porous PLGA microspheres loaded with PTHJournal of orthopaedic translation · 2025Article
- A Noninterventional, Cross-Sectional Study to Assess Patient Prostate Cancer Treatment Preferences and Experiences in Europe.Advances in therapy · 2025Article
- A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia.BMC urology · 2025Article
- Molecular mechanisms underlying cyclophosphamide-induced cognitive impairment and strategies for neuroprotection in preclinical models.Molecular and cellular biochemistry · 2024Review
- Review
- Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer.Nutrients · 2023Article
- Effect of artificial cycle with or without GnRH-a pretreatment on pregnancy and neonatal outcomes in women with PCOS after frozen embryo transfer: a propensity score matching study.Reproductive biology and endocrinology : RB&E · 2022Article
- Review
- Investigation of Specific Targeting of Triptorelin-Conjugated Dextran-Coated Magnetite Nanoparticles as a Targeted Probe in GnRHContrast media & molecular imaging · 2021Article
- Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.International journal of molecular sciences · 2020Review
- Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.Cellular and molecular life sciences : CMLS · 2020Article
- Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.Asian journal of urology · 2020Article
- Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2019Review
- Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.Therapeutic advances in urology · 2018Article
- [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].Der Urologe. Ausg. A · 2018Review
- Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.Therapeutic advances in urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient. Head-to-head studies of GnRH agonists are lacking in the field of prostate cancer. Despite the inevitable progression to castration-resistant prostate cancer (CRPC) in most patients receiving ADT, monitoring of testosterone levels needs to improve in routine practice and physicians should not overlook the benefits of continued ADT in their patients when introducing one of the various new treatment options for CRPC. For improved survival outcomes, there remains a need to tailor ADT treatment regimens, novel hormonal agents and chemotherapy according to the individual patient with advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.